该项国际、多中心回顾性研究共纳入1384例使用HD-MTX进行CNS预防的DLBCL患者,其中接受i-HD-MTX的患者为749例,接受EOT-HD-MTX的患者为635例。两组患者的基线比较一致(详见表1),CNS-IPI评分涉及的高危因素多数无统计学差异,仅在晚期患者比例有差异(...
CNS relapse in patients with DLBCL according to CNS‐IPI score and the initial therapys 16 th International Myeloma Workshop, March 1-4, 2017 | e213 and complete response was obtained in 22 patients (25%). Median progression free survival (PFS) was 36 months and median overall survival was...
DLBCL发生CNS侵犯的总体概率为5%左右,存在以下哪些因素可以使CNS侵犯的发生率明显增加?()A.发生部位在副鼻窦、性腺、乳腺、椎旁及肾上腺B.IPI评分≥3或存在≥2处结外受累C.LDH增高D.年龄大于60搜索 题目 DLBCL发生CNS侵犯的总体概率为5%左右,存在以下哪些因素可以使CNS侵犯的发生率明显增加?() A.发生部位在副...
Prophylaxis with high‐dose methotrexate significantly reduces CNS dissemination in patients with diffuse large B‐cell lymphoma (DLBCL) and high‐risk CNS‐IPI scoreIt is widely demonstrated that the PI3K-AKT-mTOR signalling is critical in normal myeloid and lymphoid development and function. Thus, ...
In the largest study to date, Schmitz et al developed and validated the “CNS-IPI” (international prognostic index) risk model in DLBCL, which incorporates the standard IPI factors, as well as kidney or adrenal gland involvement, to stratify patients into 3 risk groups: low risk (0 to 1 ...
The pt's age, IPI score, CNS-IPI score, systemic treatment, CSF evaluation, CNS prophylaxis or treatment, CNS event (yes/no), progression free survival and overall survival were recorded. Results: Thirty-one pts were evaluated. Seventeen were male. Median age was 72 years (range: 40 to ...
The risk of CNS relapse in R2CHOP-treated patients was then estimated and compared against published rates in RCHOP-treated patients based on CNS-IPI score. Results One hundred thirty-six patients with DLBCL from both cohorts (87 MC patients, 49 FIL patients) were included in this analysis. ...
To assess if immunochemotherapy influenced the prognostic value of IPI in elderly diffuse large B-cell lymphoma (DLBCL) patients, we evaluated the performa... RH Advani,H Chen,TM Habermann,... - 《British Journal of Haematology》 被引量: 125发表: 2010年 Randomized intergroup trial of first ...
RETROSPECTIVE APPLICATION OF THE CNS‐IPI TO A POPULATION OF DLBCL PATIENTS TREATED WITH IT MTX PROPHYLAXIS: A SINGLE CENTRE ANALYSISdoi:10.1002/hon.53_2881Flynn, C.McCarthy, M.Harvey, T.Flavin, R.Dunne, B.Sukor, S.Grant, C.Hematological Oncology...
CNS relapse in patients with DLBCL according to CNS-IPI score and the initial therapydoi:10.1002/hon.2439_106Verrou, E.Gerofotis, A.Karampatzakis, N.Papadopoulou, A.Keramidioti, C.Palaska, V.Papadaki, S.Katodrytou, E.Konstantinidou, P....